Barrett's Esophagus and Esophageal Adenocarcinoma: A Histopathological Perspective

Roman E Zyla; Sangeetha N Kalimuthu

doi:10.1016/j.thorsurg.2022.06.005

Barrett's Esophagus and Esophageal Adenocarcinoma: A Histopathological Perspective

Thorac Surg Clin. 2022 Nov;32(4):413-424. doi: 10.1016/j.thorsurg.2022.06.005.

Authors

Roman E Zyla¹, Sangeetha N Kalimuthu²

Affiliations

¹ Department of Laboratory Medicine and Pathobiology, University of Toronto, 27 King's College Cir, Toronto, ON M5S 1A1, Canada.
² Department of Laboratory Medicine and Pathobiology, University of Toronto, 27 King's College Cir, Toronto, ON M5S 1A1, Canada; University Health Network, Toronto, Ontario, Canada. Electronic address: sangeetha.kalimuthu@uhn.ca.

PMID: 36266029
DOI: 10.1016/j.thorsurg.2022.06.005

Abstract

Esophageal adenocarcinoma (EAC) is increasing in prevalence. Barrett's esophagus (BE) has long been recognized as the putative precursor lesion for EAC, but much is still unknown regarding its cell of origin and what molecular factors influence its neoplastic progression. Accurate pathologic assessment of BE biopsies is important for identifying patients most at risk of progressing to EAC, whereas pathologic assessment of EAC specimens plays a major role in influencing therapeutic decision-making.

Keywords: Barrett’s esophagus; Esophageal adenocarcinoma; Molecular pathogenesis; Regression grading.

Publication types

Review

MeSH terms

Adenocarcinoma* / pathology
Barrett Esophagus* / pathology
Disease Progression
Esophageal Neoplasms* / pathology
Humans

Supplementary concepts

Adenocarcinoma Of Esophagus